14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GNTA vs IDEV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. GNTA trades at $0.98 (N/M Forward P/E, 0.0% operating margin) versus IDEV at $88.40 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6); meanwhile IDEV is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNTA vs IDEV. Trailing 12-month operating profitability (GNTA 0.0% vs IDEV N/A) and valuation multiples (GNTA N/M vs IDEV N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GNTA vs IDEV Key Questions & Quantitative Answers
As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. GNTA trades at $0.98 (N/M Forward P/E, 0.0% operating margin) versus IDEV at $88.40 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6); meanwhile IDEV is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GNTA leads the Growth & Scale pillar: GNTA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IDEV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GNTA generates N/A in USD-normalized revenue versus N/A for IDEV. In operating R&D and SG&A reinvestment, GNTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IDEV.
GNTA and IDEV trade at balanced relative valuation multiples. GNTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNTA (-38.0% ROE) versus IDEV (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, GNTA carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 132% Vol realized risk). By comparison, IDEV carries 26.3% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 19% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.